Discussion between experts on novel and emerging HER2-targeted and TROP-2 directed therapies for patients with HER2-low, hormone receptor positive, and triple-negative advanced breast cancer.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/novel-adcs-in-advanced-breast-cancer/18635-27501
- Start Date: 2024-03-20 05:00:00
- End Date: 2024-03-20 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 40000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 40000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest